Schistosoma Haematobium Infections and Praziquantel

U

University of Khartoum

Status and phase

Completed
Phase 3

Conditions

Schistosomiasis

Treatments

Drug: praziquantel

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01558336
Schistosmiasis

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.

Full description

A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.

Enrollment

520 patients

Sex

All

Ages

6 to 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

School children

Exclusion criteria

Taking praziquantel

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

520 participants in 1 patient group

Praziguantel
Experimental group
Description:
tablet single dose
Treatment:
Drug: praziquantel

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems